Log in to your Inderes Free account to see all free content on this page.
OncoZenge
6.40 SEK
+2.56 %
Less than 1K followers
ONCOZ
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Valuation
Income statement
Quarter data
Quarter data
Financial statements, revenue, EBIT, valuation metrics, and quarterly estimates for OncoZenge
| Q4/24 | 2024 | Q1/25 | Q2/25 | Q3/25 | Q4/25 | 2025 | Q1/26 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 2.7 | 2.7 | ||||||
| EBITDA | -2.5 | -8.7 | 0.0 | -2.6 | -3.5 | |||
| EBIT | -2.5 | -8.7 | 0.0 | -2.6 | -3.5 | -9.7 | -15.8 | -6.8 |
| EBIT-% | 1.5 % | -592.6 % | ||||||
| Profit before taxes | -2.5 | -8.7 | 0.0 | -2.6 | -3.5 | -9.9 | -15.9 | -7.1 |
| Net income | -2.5 | -8.7 | 0.0 | -2.6 | -3.5 | -9.9 | -15.9 | -7.1 |
Login required
This content is only available for logged in users